Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen to Spend $23.3M to Expand Scottish Facility; Will Become New Euro HQ

NEW YORK, May 2 (GenomeWeb News) - Invitrogen will spend £12.7 million ($23.3 million) to "consolidate" and "expand" its operations in Scotland, the Scottish Enterprise, the nation's main economic-development agency, said today.

 

Among the expansion is a plan to create a new global corporate research center in Inchinnan in the outskirts of Glasgow, which will also become Invitrogen's new European headquarters.

The move, which will be supported with a £4.3-million investment from Scotland's Deputy First Minister Nicol Stephen, will "potentially" create 45 new jobs and "safeguard" 555 existing Invitrogen positions in Scotland, the Scottish Enterprise said. Asked whether the jobs had been in jeopardy, a Scottish Enterprise spokesperson said Invitrogen could have expended anyplace in Europe, but since it chose Scotlandthose positions will remain "safeguarded."

 

Terms of the expansion call for Invitrogen to "amalgamate" its current manufacturing and product development sites across Scotlandinto the InchinnanBusinessPark.

 

The base, which will be moved into a 90,000-square-foot facility, will become the firm's European headquarters, and will have additional resources for R&D, sales, finance, legal, and customer services functions.

 

The move will "enable the company to meet increased business demand in a more cost effective way and has the potential for future expansion," Bernd Brust, vice president and general manager of Invitrogen Europe, said in a statement.

 

An Invitrogen spokesperson said construction on the new facility will begin this summer, and it is slated to open in the fall of 2007. Invitrogen will finish transferring staff and operations at that time, the spokesperson added.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.